reported that a combination of metformin and sorafenib could synergistically inhibit HIF-2α expression, thereby increasing sensitivity of hypoxic HCC cells to sorafenib, and hindering EMT. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.